Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Bianchini G, et al. Among authors: hatzis c. J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. J Clin Oncol. 2010. PMID: 20805453
Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Symmans WF, et al. Among authors: hatzis c. J Clin Oncol. 2010 Sep 20;28(27):4111-9. doi: 10.1200/JCO.2010.28.4273. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697068 Free PMC article.
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Iwamoto T, et al. Among authors: hatzis c. J Clin Oncol. 2012 Mar 1;30(7):729-34. doi: 10.1200/JCO.2011.36.2574. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291085
Gene signature-guided dasatinib therapy in metastatic breast cancer.
Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Pusztai L, et al. Among authors: hatzis c. Clin Cancer Res. 2014 Oct 15;20(20):5265-71. doi: 10.1158/1078-0432.CCR-14-0800. Epub 2014 Aug 29. Clin Cancer Res. 2014. PMID: 25172932 Clinical Trial.
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Symmans WF, et al. Among authors: hatzis c. J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135148 Free PMC article.
221 results